Better Biotechnology ETF: First Trust FBT vs. VanEck BBH

Impact · against what's priced in

The article provides no new fundamental catalysts for the mentioned biotechnology companies, as the recommendations are based on existing portfolio weights and general industry status. The mentions of ILMN, AMGN, and GILD confirm their roles as industry leaders or top holdings, which is already reflected in their current valuations.

AMGN+0.00

Already priced in

The price assumes

raised full-year revenue guidance of $38.2-$39.4 billion